389 related articles for article (PubMed ID: 23342996)
1. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
2. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
[TBL] [Abstract][Full Text] [Related]
5. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.
Bergmann-Leitner ES; Duncan EH; Mease RM; Angov E
Malar J; 2012 Sep; 11():315. PubMed ID: 22958482
[TBL] [Abstract][Full Text] [Related]
6. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
Lyon JA; Angov E; Fay MP; Sullivan JS; Girourd AS; Robinson SJ; Bergmann-Leitner ES; Duncan EH; Darko CA; Collins WE; Long CA; Barnwell JW
PLoS One; 2008 Jul; 3(7):e2830. PubMed ID: 18665258
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
Stoute JA; Gombe J; Withers MR; Siangla J; McKinney D; Onyango M; Cummings JF; Milman J; Tucker K; Soisson L; Stewart VA; Lyon JA; Angov E; Leach A; Cohen J; Kester KE; Ockenhouse CF; Holland CA; Diggs CL; Wittes J; Heppner DG;
Vaccine; 2007 Jan; 25(1):176-84. PubMed ID: 16388879
[TBL] [Abstract][Full Text] [Related]
8. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
Ellis RD; Wu Y; Martin LB; Shaffer D; Miura K; Aebig J; Orcutt A; Rausch K; Zhu D; Mogensen A; Fay MP; Narum DL; Long C; Miller L; Durbin AP
PLoS One; 2012; 7(10):e46094. PubMed ID: 23056238
[TBL] [Abstract][Full Text] [Related]
10. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
11. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
[TBL] [Abstract][Full Text] [Related]
12. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
[TBL] [Abstract][Full Text] [Related]
14. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF; Angov E; Kester KE; Diggs C; Soisson L; Cummings JF; Stewart AV; Palmer DR; Mahajan B; Krzych U; Tornieporth N; Delchambre M; Vanhandenhove M; Ofori-Anyinam O; Cohen J; Lyon JA; Heppner DG;
Vaccine; 2006 Apr; 24(15):3009-17. PubMed ID: 16356603
[TBL] [Abstract][Full Text] [Related]
15. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.
Malkin E; Long CA; Stowers AW; Zou L; Singh S; MacDonald NJ; Narum DL; Miles AP; Orcutt AC; Muratova O; Moretz SE; Zhou H; Diouf A; Fay M; Tierney E; Leese P; Mahanty S; Miller LH; Saul A; Martin LB
PLoS Clin Trials; 2007; 2(4):e12. PubMed ID: 17415408
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
20. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR.
Morgan WD; Lock MJ; Frenkiel TA; Grainger M; Holder AA
Mol Biochem Parasitol; 2004 Nov; 138(1):29-36. PubMed ID: 15500913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
